BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol 2015; 7(5): 738-752 [PMID: 25914774 DOI: 10.4254/wjh.v7.i5.738] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 27] [Article Influence: 5.1] [Reference Citation Analysis]
Number Citing Articles
1 Thornton LM, Geller BS, Pepin EW, Shah JL, Kapp M, Toskich BB. Safety of Radioembolization in the Setting of Angiographically Apparent Arterioportal Shunting. Journal of Vascular and Interventional Radiology 2018;29:1511-8. [DOI: 10.1016/j.jvir.2018.06.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
2 Voruganti IS, Godwin JL, Adrain A, Feller E. A Woman with Black Beads in Her Stomach: Severe Gastric Ulceration Caused by Yttrium-90 Radioembolization. Case Rep Med. 2018;2018:1413724. [PMID: 29849654 DOI: 10.1155/2018/1413724] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
3 Auditore L, Amato E, Boughdad S, Meyer M, Testart N, Cicone F, Beigelman-Aubry C, Prior JO, Schaefer N, Gnesin S. Monte Carlo 90Y PET/CT dosimetry of unexpected focal radiation-induced lung damage after hepatic radioembolisation. Phys Med Biol 2020;65:235014. [PMID: 33245055 DOI: 10.1088/1361-6560/abbc80] [Reference Citation Analysis]
4 Kleynhans J, Grobler AF, Ebenhan T, Sathekge MM, Zeevaart J. Radiopharmaceutical enhancement by drug delivery systems: A review. Journal of Controlled Release 2018;287:177-93. [DOI: 10.1016/j.jconrel.2018.08.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
5 Pellegrinelli J, Chevallier O, Manfredi S, Dygai-Cochet I, Tabouret-Viaud C, Nodari G, Ghiringhelli F, Riedinger JM, Popoff R, Vrigneaud JM, Cochet A, Aho S, Latournerie M, Loffroy R. Transarterial Radioembolization of Hepatocellular Carcinoma, Liver-Dominant Hepatic Colorectal Cancer Metastases, and Cholangiocarcinoma Using Yttrium90 Microspheres: Eight-Year Single-Center Real-Life Experience. Diagnostics (Basel) 2021;11:122. [PMID: 33466706 DOI: 10.3390/diagnostics11010122] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Patel R, Roberson J, Prakash D, Meyer R, Hogan L, Azmy C, Suprenant V, Ryu S, Stessin A. Potential alternative treatment approach for pediatric patient with diffusely infiltrative primary rhabdomyosarcoma of the liver. Rep Pract Oncol Radiother 2021;26:143-8. [PMID: 34046225 DOI: 10.5603/RPOR.a2021.0008] [Reference Citation Analysis]
7 Pan LH, Zhao C, Ma YL. Is Y90 Radioembolization Superior or Comparable to Transarterial Chemoembolization for Treating Hepatocellular Carcinoma? Gastroenterology 2017;152:1627-8. [PMID: 28384449 DOI: 10.1053/j.gastro.2016.10.048] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
8 Morisco F, Camera S, Guarino M, Tortora R, Cossiga V, Vitiello A, Cordone G, Caporaso N, Di Costanzo GG; Italian Liver Cancer (ITA.LI.CA) group. Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: a pilot case-control study. Oncotarget 2018;9:17483-90. [PMID: 29707122 DOI: 10.18632/oncotarget.24756] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
9 Mazzanti R, Arena U, Tassi R. Hepatocellular carcinoma: Where are we? World J Exp Med 2016; 6(1): 21-36 [PMID: 26929917 DOI: 10.5493/wjem.v6.i1.21] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 68] [Article Influence: 12.5] [Reference Citation Analysis]
10 Mak LY, Cruz-Ramón V, Chinchilla-López P, Torres HA, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Bailey HH, Méndez-Sánchez N, Yuen MF, Hwang JP. Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. Am Soc Clin Oncol Educ Book 2018;38:262-79. [PMID: 30231359 DOI: 10.1200/EDBK_200939] [Cited by in Crossref: 62] [Cited by in F6Publishing: 43] [Article Influence: 15.5] [Reference Citation Analysis]
11 Song JE, Jung KS, Kim DY, Song K, Won JY, Lee HW, Kim BK, Kim SU, Park JY, Ahn SH, Seong J, Han KH. Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Int J Radiat Oncol Biol Phys 2017;99:396-406. [PMID: 28871990 DOI: 10.1016/j.ijrobp.2017.05.049] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
12 Voutsinas N, Lekperic S, Barazani S, Titano JJ, Heiba SI, Kim E. Treatment of Primary Liver Tumors and Liver Metastases, Part 1: Nuclear Medicine Techniques. J Nucl Med 2018;59:1649-54. [PMID: 30072501 DOI: 10.2967/jnumed.116.186346] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
13 Jung JW, Foster HS, Tabori NE, Sivananthan G. Yttrium-90 Radioembolization Complicated by Colitis. J Vasc Interv Radiol 2021;32:1698-9. [PMID: 34325005 DOI: 10.1016/j.jvir.2021.07.016] [Reference Citation Analysis]
14 Wang EA, Stein JP, Bellavia RJ, Broadwell SR. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres. Int J Clin Pract 2017;71:e12972. [DOI: 10.1111/ijcp.12972] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
15 Salman A, Simoneau E, Hassanain M, Chaudhury P, Boucher LM, Valenti D, Cabrera T, Nudo C, Metrakos P. Combined sorafenib and yttrium-90 radioembolization for the treatment of advanced hepatocellular carcinoma. Curr Oncol 2016;23:e472-80. [PMID: 27803608 DOI: 10.3747/co.23.2827] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
16 Granito A, Bolondi L. Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis. The Lancet Oncology 2017;18:e101-12. [DOI: 10.1016/s1470-2045(16)30569-1] [Cited by in Crossref: 62] [Cited by in F6Publishing: 35] [Article Influence: 12.4] [Reference Citation Analysis]
17 Younge KC, Lee C, Moran JM, Feng M, Novelli P, Prisciandaro JI. Failure mode and effects analysis in a dual-product microsphere brachytherapy environment. Pract Radiat Oncol 2016;6:e299-306. [PMID: 27155761 DOI: 10.1016/j.prro.2016.03.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
18 Gallio E, Richetta E, Finessi M, Stasi M, Pellerito RE, Bisi G, Ropolo R. Calculation of tumour and normal tissue biological effective dose in 90 Y liver radioembolization with different dosimetric methods. Physica Medica 2016;32:1738-44. [DOI: 10.1016/j.ejmp.2016.10.023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
19 Faltermeier C, Busuttil RW, Zarrinpar A. A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. Diseases 2015;3:221-52. [PMID: 28943622 DOI: 10.3390/diseases3040221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
20 Abraham JA, Yeghiazaryan K, Golubnitschaja O. Selective internal radiation therapy in treatment of hepatocellular carcinoma: new concepts of personalization. Per Med 2016;13:347-60. [PMID: 29749819 DOI: 10.2217/pme-2016-0014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
21 Kantor O, Baker MS. Hepatocellular Carcinoma: Surgical Management and Evolving Therapies. Cancer Treat Res 2016;168:165-83. [PMID: 29206369 DOI: 10.1007/978-3-319-34244-3_8] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Zhang ZY, Zhang EL, Zhang BX, Zhang W. Surgery for hepatocellular carcinoma with tumor thrombosis in inferior vena cava: A case report. World J Clin Cases 2021; 9(36): 11495-11503 [DOI: 10.12998/wjcc.v9.i36.11495] [Reference Citation Analysis]
23 Inchingolo R, Posa A, Mariappan M, Spiliopoulos S. Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions. World J Gastroenterol 2019;25:4614-28. [PMID: 31528090 DOI: 10.3748/wjg.v25.i32.4614] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 37] [Article Influence: 13.3] [Reference Citation Analysis]
24 Kim Y, Lee HA, Lee JS, Jeon MY, Kim BK, Park JY, Kim DY, Ahn SH, Um SH, Seo YS, Kim SU. Association Between Curative Treatment after Transarterial Radioembolization and Better Survival Outcomes in Patients with Hepatocellular Carcinoma. Cancer Invest 2021;39:274-83. [PMID: 33356630 DOI: 10.1080/07357907.2020.1870126] [Reference Citation Analysis]
25 Kollmann D, Selzner N, Selzner M. Bridging to liver transplantation in HCC patients. Langenbecks Arch Surg. 2017;402:863-871. [PMID: 28755240 DOI: 10.1007/s00423-017-1609-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
26 Papamichail M, Pizanias M, Heaton ND, M P, M P, Nd H. Minimizing the risk of small-for-size syndrome after liver surgery. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00230-7. [PMID: 34961675 DOI: 10.1016/j.hbpd.2021.12.005] [Reference Citation Analysis]
27 Abraham JA, Golubnitschaja O. Time for paradigm change in management of hepatocellular carcinoma: is a personalized approach on the horizon? Per Med 2016;13:455-67. [PMID: 29767598 DOI: 10.2217/pme-2016-0013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
28 Filippi L, Schillaci O, Cianni R, Bagni O. Yttrium-90 resin microspheres and their use in the treatment of intrahepatic cholangiocarcinoma. Future Oncology 2018;14:809-18. [DOI: 10.2217/fon-2017-0443] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
29 Bomberna T, Koudehi GA, Claerebout C, Verslype C, Maleux G, Debbaut C. Transarterial drug delivery for liver cancer: numerical simulations and experimental validation of particle distribution in patient-specific livers. Expert Opin Drug Deliv 2021;18:409-22. [PMID: 33210955 DOI: 10.1080/17425247.2021.1853702] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Lau WY, Teoh YL, Win KM, Lee RC, de Villa VH, Kim YH, Liang PC, Santos-Ocampo RS, Lo RH, Lim KB, Tai DW, Ng DC, Irani FG, Gogna A, Chow PK. Current role of selective internal radiation with yttrium-90 in liver tumors. Future Oncol 2016;12:1193-204. [PMID: 27007495 DOI: 10.2217/fon-2016-0035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
31 Iezzi R, Bilhim T, Crocetti L, Peynircioglu B, Goldberg S, Bilbao JI, Sami A, Akhan O, Scalise P, Giuliante F, Pompili M, Valentini V, Gasbarrini A, Colosimo C, Manfredi R. "Primum Non Nocere" in Interventional Oncology for Liver Cancer: How to Reduce the Risk for Complications? Life (Basel) 2020;10:E180. [PMID: 32899925 DOI: 10.3390/life10090180] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Loffroy R, Ronot M, Greget M, Bouvier A, Mastier C, Sengel C, Tselikas L, Arnold D, Maleux G, Pelage JP, Pellerin O, Peynircioglu B, Sangro B, Schaefer N, Urdániz M, Kaufmann N, Bilbao JI, Helmberger T, Vilgrain V; CIRT-FR Principal Investigators. Short-term Safety and Quality of Life Outcomes Following Radioembolization in Primary and Secondary Liver Tumours: a Multi-centre Analysis of 200 Patients in France. Cardiovasc Intervent Radiol 2021;44:36-49. [PMID: 32975600 DOI: 10.1007/s00270-020-02643-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]